{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"44.0"}]}],"title":"≤ 0.0032%"},{"categories":[{"measurements":[{"groupId":"OG000","value":"12.0"}]}],"title":">0.0032% - ≤ 0.01%"},{"categories":[{"measurements":[{"groupId":"OG000","value":"20.0"}]}],"title":">0.01% - ≤ 0.1%"},{"categories":[{"measurements":[{"groupId":"OG000","value":"8.0"}]}],"title":">0.1% - ≤ 1%"},{"categories":[{"measurements":[{"groupId":"OG000","value":"8.0"}]}],"title":">1% - ≤ 10%"},{"categories":[{"measurements":[{"groupId":"OG000","value":"8.0"}]}],"title":">10%"}],"denoms":[{"counts":[{"groupId":"OG000","value":"25"}],"units":"Participants"}],"description":"MMR is defined as ≤ 0.1% BCR-ABL/control gene (ABL) % by international scale, or equivalent to ≥ 3 log reduction of BCR-ABL transcript from standardized baseline, measured by RQ-PCR (Real time quantitative polymerase chain reaction). BCR-ABL is the fusion gene from breakpoint cluster region and Abelson genes. BCR-ABL ratio by percentage: \\> 0.0032 to ≤ 0.01% is equal to a log reduction category of \\>= 4 to \\<4.5 -log reduction (MR4); BCR-ABL ratio by percentage: \\<=0.0032% is equal to a log reduction category of \\>= 4.5-log reduction (MMR4.5)","groups":[{"description":"Patients newly diagnosed in Chronic phase. Diagnosis within 6 months of date of first cytogenetic analysis confirming Philadelphia chromosome with (9;22) translocation by standard conventional cytogenetic analysis.","id":"OG000","title":"Newly Diagnosed and Untreated Ph+ CML in First CP"}],"paramType":"NUMBER","populationDescription":"Full Analysis Set (FAS): All patients who received at least one dose of study medication","reportingStatus":"POSTED","timeFrame":"up to 66 cycles (1 cycle = 28 days)","title":"Best BCR-ABL Ratio Categories for Newly Diagnosed Ph+ CML-CP - Overall","type":"SECONDARY","unitOfMeasure":"Percentage of participants"}